NCT04542161View on ClinicalTrials.gov

Assessment of N-Acetylcysteine as Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

PHASE2RecruitingINTERVENTIONAL
Enrollment

95

Participants

Timeline

Start Date

September 1, 2020

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
Chronic Fatigue SyndromeMyalgic Encephalomyelitis
Interventions
DRUG

NAC 900mg/day

self administer NAC 900mg/day caplets for a four week period

DRUG

NAC 3600mg/day

self administer NAC 3600mg/day caplets for a four week period

DRUG

NAC 0mg/day (Placebo)

self administer NAC 0mg/day (placebo) caplets for a four week period

Trial Locations (1)

10021

RECRUITING

Weill Cornell Medicine, New York

All Listed Sponsors
collaborator

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

lead

Weill Medical College of Cornell University

OTHER